Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + famitinib
- Development stage
- Discontinued
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dalpiciclib (SHR6390) is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Famitinib (SHR 1020) is an orally bioavailable small molecule tyrosine kinase inhibitor targeting multiple receptors including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR), and proto-oncogene protein c-kit. The combination of dalpiciclib and famitinib is being investigated in clinical trials for the treatment of HR+/HER2- advanced or metastatic breast cancer[1][4][7]. Dalpiciclib induces G1 cell cycle arrest by inhibiting CDK4/6 activity[3][6][8], while famitinib inhibits angiogenesis and tumor cell proliferation through its multi-targeted tyrosine kinase inhibition[2][5].
- Other names
- dalpiciclibfamitinib maleatefamitinib
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)FLT3 (Fms related receptor tyrosine kinase 3)PDGFR (PDGFR family)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on dalpiciclib + famitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + famitinib.